Link Details
- Metabolite
- HMDB0000122 (D-Glucose)
- DrugBank ID
- DB09038
- Drug Name
- Empagliflozin
- Effect
- Decrease
- Biospecimen
- Blood
- P-value
- Not Available
- Beta Estimator
- Not Available
- Percent Change
- Not Available
- Pearson Correlation Coefficient
- Not Available
- Comments
- Not Available
- Ghezzi C, Yu AS, Hirayama BA, Kepe V, Liu J, Scafoglio C, Powell DR, Huang SC, Satyamurthy N, Barrio JR, Wright EM: Dapagliflozin Binds Specifically to Sodium-Glucose Cotransporter 2 in the Proximal Renal Tubule. J Am Soc Nephrol. 2017 Mar;28(3):802-810. doi: 10.1681/ASN.2016050510. Epub 2016 Sep 12. [PubMed:27620988 ]
- Heise T, Seman L, Macha S, Jones P, Marquart A, Pinnetti S, Woerle HJ, Dugi K: Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther. 2013 Dec;4(2):331-45. doi: 10.1007/s13300-013-0030-2. Epub 2013 Jul 10. [PubMed:23838841 ]
- Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ: A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013 Aug;15(8):721-8. doi: 10.1111/dom.12081. Epub 2013 Mar 4. [PubMed:23398530 ]